BFC
LLY icon

Blue Fin Capital’s Eli Lilly LLY Stock Holding History

Blue Fin Capital’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.27M Sell
10,075
-553
-5% -$561K 1.52% 15
2025
Q4 		$11.4M Sell
10,628
-263
-2% -$251K 1.77% 14
2025
Q3 		$8.31M Sell
10,891
-156
-1% -$116K 1.31% 15
2025
Q2 		$8.61M Buy
11,047
+33
+0.3% +$25.6K 1.47% 14
2025
Q1 		$9.1M Sell
11,014
-74
-0.7% -$61.6K 1.76% 13
2024
Q4 		$8.56M Buy
11,088
+17
+0.2% +$14.1K 1.58% 13
2024
Q3 		$9.81M Buy
11,071
+221
+2% +$199K 1.86% 11
2024
Q2 		$9.82M Buy
10,850
+100
+0.9% +$80K 1.96% 11
2024
Q1 		$8.36M Buy
10,750
+535
+5% +$381K 1.86% 11
2023
Q4 		$5.95M Buy
10,215
+314
+3% +$183K 1.53% 14
2023
Q3 		$5.32M Buy
9,901
+86
+0.9% +$44.3K 1.55% 15
2023
Q2 		$4.6M Buy
9,815
+42
+0.4% +$17.6K 1.31% 16
2023
Q1 		$4.19M Buy
9,773
+242
+3% +$81.6K 1.35% 17
2022
Q4 		$3.49M Sell
9,531
-252
-3% -$89.3K 1.28% 21
2022
Q3 		$3.16M Sell
9,783
-3
-0% -$951 1.2% 23
2022
Q2 		$3.17M Sell
9,786
-32
-0.3% -$9.61K 1.12% 23
2022
Q1 		$2.81M Sell
9,818
-21
-0.2% -$5.41K 0.81% 32
2021
Q4 		$2.72M Buy
9,839
+91
+0.9% +$23.1K 0.75% 33
2021
Q3 		$2.25M Sell
9,748
-102
-1% -$25.2K 0.69% 38
2021
Q2 		$2.26M Sell
9,850
-287
-3% -$57.6K 0.7% 37
2021
Q1 		$1.89M Sell
10,137
-180
-2% -$35.2K 0.65% 40
2020
Q4 		$1.74M Sell
10,317
-172
-2% -$25.7K 0.62% 42
2020
Q3 		$1.55M Sell
10,489
-218
-2% -$33.7K 0.63% 43
2020
Q2 		$1.76M Sell
10,707
-265
-2% -$40.7K 0.78% 31
2020
Q1 		$1.52M Sell
10,972
-100
-0.9% -$13.7K 0.84% 33
2019
Q4 		$1.45M Sell
11,072
-57
-0.5% -$6.61K 0.68% 43
2019
Q3 		$1.24M Sell
11,129
-490
-4% -$54.6K 0.65% 48
2019
Q2 		$1.29M Buy
11,619
+101
+0.9% +$11.9K 0.66% 49
2019
Q1 		$1.49M Sell
11,518
-382
-3% -$46.5K 0.78% 38
2018
Q4 		$1.38M Sell
11,900
-489
-4% -$54.6K 0.82% 36
2018
Q3 		$1.33M Sell
12,389
-345
-3% -$34.5K 0.66% 45
2018
Q2 		$1.09M Sell
12,734
-70
-0.5% -$5.75K 0.58% 50
2018
Q1 		$990K Sell
12,804
-255
-2% -$20.5K 0.56% 56
2017
Q4 		$1.1M Buy
13,059
+15
+0.1% +$1.28K 0.64% 48
2017
Q3 		$1.11M Sell
13,044
-110
-0.8% -$9.02K 0.68% 43
2017
Q2 		$1.08M Sell
13,154
-890
-6% -$72.6K 0.7% 45
2017
Q1 		$1.18M Sell
14,044
-375
-3% -$30K 0.72% 43
2016
Q4 		$1.06M Buy
14,419
+1,655
+13% +$123K 0.7% 46
2016
Q3 		$1.02M Sell
12,764
-730
-5% -$58.4K 0.83% 40
2016
Q2 		$1.06M Sell
13,494
-190
-1% -$14.3K 0.88% 37
2016
Q1 		$985K Sell
13,684
-1,705
-11% -$129K 0.84% 40
2015
Q4 		$1.3M Sell
15,389
-41
-0.3% -$3.4K 1% 28
2015
Q3 		$1.29M Sell
15,430
-155
-1% -$13.1K 1% 28
2015
Q2 		$1.3M Sell
15,585
-90
-0.6% -$6.86K 0.94% 29
2015
Q1 		$1.14M Buy
15,675
+200
+1% +$14.2K 0.82% 38
2014
Q4 		$1.07M Buy
15,475
+945
+7% +$63.8K 0.81% 43
2014
Q3 		$942K Buy
14,530
+190
+1% +$12K 0.75% 44
2014
Q2 		$892K Buy
14,340
+100
+0.7% +$5.97K 0.71% 48
2014
Q1 		$838K Buy
14,240
+315
+2% +$17.6K 0.74% 46
2013
Q4 		$710K Buy
+13,925
New +$697K 0.63% 58

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Blue Fin Capital's LLY Position: Q1 2026 in Review

Blue Fin Capital reduced its Eli Lilly (LLY) stake by 5.2% in Q1 2026, selling an estimated $561K and leaving 10,075 shares worth $9.27M. The position accounts for 1.52% of the portfolio, ranked #15.

Blue Fin Capital first reported a position in LLY in Q4 2013 and has held it in 50 quarters since. The position peaked at $11.4M in Q4 2025. 4,356 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Blue Fin Capital held 10,075 shares of Eli Lilly worth $9.27M as of Q1 2026.
  • Blue Fin Capital sold 553 Eli Lilly shares in Q1 2026, an estimated $561K.
  • Eli Lilly made up 1.52% of Blue Fin Capital's portfolio in Q1 2026, its #15 holding.
  • Blue Fin Capital first reported a position in Eli Lilly in Q4 2013 and has held it in 50 quarters since.
  • Blue Fin Capital's Eli Lilly position peaked at $11.4M in Q4 2025.
  • 4,356 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Blue Fin Capital's 13F filing for Q1 2026, filed 28 May 2026.